SI
SI
discoversearch

Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3189 142 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Incyte markets the first JAK inhibitor approved for any use, Jakafi (ruxolitinib). Add an interesting pipeline, and INCY is fun to follow, if not own. Please contribute, and good luck!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3189Tuck, I was bit sarcastic. That is all! Herve is well aware that Epa is "mMiljenko Zuanic-May 11
3188What do you mean? He bought near $60 like you (and me, via sold puts as usual).tuck-May 11
3187Is Herve damn?? secfilings.nasdaq.comMiljenko Zuanic-May 10
3186Thnx. Overall, street view/see Ruxo success in acute/chronic GVHD. They need somMiljenko Zuanic-May 5
3185 cool..... bloodjournal.org >> Topical ruxolitinib, unlike corticostescaram(o)uche-May 4
3184OT, again >> Look at the daily chart for qure and once versus that for sgscaram(o)uche-April 24
3183>> now playing with gains << Cool. House money, nothing feels bettscaram(o)uche-April 24
3182RE:VKTX "force selling"---> it may be!? Secondary @5 was OK, nothinMiljenko Zuanic-April 24
3181 So you bought after the disaster, and believe Epa still lives? Interesting, hoscaram(o)uche-April 24
3180Because of the good safety, I would bump dose to 300mg/day and continue to combiMiljenko Zuanic-April 24
3179believe that Epa is not dead Which remaining combos(s) are of interest? Edit: Ttuck-April 24
3178<How could any FDA be more liberal than the Gottlieb FDA?> They (revieweMiljenko Zuanic-April 24
3177>> Hope NEW FDA will be more open for suggestions!!? << How could ascaram(o)uche-April 24
3176Not clear is it JAK2 related, not related to platelets count (which actually decMiljenko Zuanic-April 24
3175 Therapeutic window!! Large enough that a panel of FDA-deemed experts said yes!scaram(o)uche-April 24
3174Never hear so much (and so many) incompetent panels of RA "experts"! Miljenko Zuanic1April 23
3173Now the FDA AdCom vote. Two doses. 10-5 in favor of 2mg, and 10-5 against the tuck-April 23
3172OT: ONCE benefited the most! EOMMiljenko Zuanic-April 10
3171Ah, OK. Thought the big move was all avxs sentiment. Thanks!scaram(o)uche-April 10
3170Seems that AAV5 ( AMT-061) has lower pre-existing mAbs titar! They are going strMiljenko Zuanic-April 9
3169OT >> OT: Nice move in QURE, too! << Look at the daily chart for qscaram(o)uche-April 9
3168RA.... I still do not understand the fast turnaround from the baricitinib CRLscaram(o)uche-April 9
3167Indeed, strong data for JAK1 Upadacitinib. Competition for GLPG/GILD too. Two Miljenko Zuanic-April 9
3166AbbVie scores a clinical win with its JAK1 inhibitor in RA. Not good news for Ituck-April 9
3165>> How big is this limb we're on?? << Twig.scaram(o)uche-April 6
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.